Oncimmune Regulatory News (ONC)

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Exercise of Options and Issue of Shares

and extension of 2007 Share Option Scheme

Nottingham, UK - 20 July 2017: Oncimmune Holdings plc (AIM: ONC) a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology has received notification from an option holder to exercise options over 25,000 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 0.02 pence per share.

Application has been made for the 25,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 24 July 2017. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 51,049,404 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

In addition, options that had been granted on 17 December 2007 under the 2007 Share Option Scheme to existing employees over 6,900 Ordinary Shares, and to a consultant over 12,450 Ordinary Shares are due to expire after 10 years on 17 December 2017. The exercise price of these options is £0.8296. The Board has agreed to extend the term of these options by a further 12 months to 17 December 2018.

 For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny

+44 (0) 203 829 5000

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708